Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat for NAFLD in Gout Patients
NCT04772352Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of febuxostat in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoints: Liver fat content of subjects in different groups at 48 weeks and Serum uric acid levels of subjects in different groups at 48 weeks. Status: unknown.
02
Drugs
febuxostat
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04772352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772352.